CoChat

Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia

Open access

The DOI matches its Crossref record; 52 of the 53 references it cites were found in a registry or an index.

Abstract

Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is highly promising but requires robust T-cell expansion and engraftment. A T-cell defect in chronic lymphocytic leukemia (CLL) due to disease and/or therapy impairs ex vivo expansion and response to CAR T cells. To evaluate the effect of ibrutinib treatment on the T-cell compartment in CLL as it relates to CAR T-cell generation, we examined the phenotype and function of T cells in a cohort of CLL patients during their course of treatment with ibrutinib. We found that ≥5 cycles of ibrutinib therapy improved the expansion of CD19-directed CAR T cells (CTL019), in association with decreased expression of the immunosuppressive molecule programmed cell death 1 on T cells and of CD200 on B-CLL cells. In support of these findings, we observed that 3 CLL patients who had been treated with ibrutinib for ≥1 year at the time of T-cell collection had improved ex vivo and in vivo CTL019 expansion, which correlated positively together and with clinical response. Lastly, we show that ibrutinib exposure does not impair CAR T-cell function in vitro but does improve CAR T-cell engraftment, tumor clearance, and survival in human xenograft models of resistant acute lymphocytic leukemia and CLL when administered concurrently. Our collective findings indicate that ibrutinib enhances CAR T-cell function and suggest that clinical trials with combination therapy are warranted. Our studies demonstrate that improved T-cell function may also contribute to the efficacy of ibrutinib in CLL. These trials were registered at www.clinicaltrials.gov as #NCT01747486, #NCT01105247, and #NCT01217749.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2015-11-679134

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 52 references

Cited by

See all 494

Metadata

Authors
Fraietta, J. A., Beckwith, K. A., Patel, P. R., Ruella, M., Zheng, Z., Barrett, D. M., Lacey, S. F., Melenhorst, J. J., McGettigan, S. E., Cook, D. R., Zhang, C., Xu, J., Do, P., Hulitt, J., Kudchodkar, S. B., Cogdill, A. P., Gill, S., Porter, D. L., Woyach, J. A., Long, M., Johnson, A. J., Maddocks, K., Muthusamy, N., Levine, B. L., June, C. H., Byrd, J. C., & Maus, M. V.
Affiliations
  • Abramson Cancer Center (US)
  • The Ohio State University (US)
  • Children's Hospital of Philadelphia (US)
  • Center for Cellular Immunotherapies and
  • Harvard University (US)
Corresponding author
  • Fraietta, Joseph A.
  • Beckwith, Kyle A.
  • Byrd, John C.
  • Maus, Marcela V.
Venue
Blood
Published
2016-03-03
Volume
127
Issue
9
Pages
1117-1127
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2296829012
Cited by
474
References
53
Citations by year
2026: 26 · 2025: 26 · 2024: 35 · 2023: 37 · 2022: 59 · 2021: 70 · 2020: 71 · 2019: 56 · 2018: 42 · 2017: 30 · 2016: 21
FWCI
26.79
Type
journal article
Language
en
Open access
Locations
  • Blood (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (4p01ca081534-16)
  • National Cancer Institute (P01CA095426, T32CA009140, R35 CA198183, R01CA165206, K23CA178183, K08CA166039, P30CA016058, R01CA177292, P30CA016520, P01-CA-081534)
Topics
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
ibrutinib, CAR T-cell therapy, CD19 CAR T cells, chronic lymphocytic leukemia, acute lymphoblastic leukemia, T cell engraftment, T cell expansion, PD-1, CD200, combination therapy, xenograft models
MeSH terms
Adenine, Administration, Oral, Aged, Animals, Cytotoxicity, Immunologic, Demography, Disease Models, Animal, Humans, Immunosuppression Therapy, Male, Middle Aged, Piperidines, Pyrazoles, Pyrimidines, Receptors, Antigen, T-Cell, T-Lymphocytes, Time Factors, Leukemia, Lymphocytic, Chronic, B-Cell, Antigens, CD, Treatment Outcome, Gene Transfer Techniques, Drug Resistance, Neoplasm, K562 Cells, Cell Line, Tumor, Cell Proliferation, Mice, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. https://app.cochat.ai/papers/10.1182/blood-2015-11-679134
The paper
Fraietta, J. A., Beckwith, K. A., Patel, P. R., Ruella, M., Zheng, Z., Barrett, D. M., Lacey, S. F., Melenhorst, J. J., McGettigan, S. E., Cook, D. R., Zhang, C., Xu, J., Do, P., Hulitt, J., Kudchodkar, S. B., Cogdill, A. P., Gill, S., Porter, D. L., Woyach, J. A., . . . Maus, M. V. (2016). Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood. https://doi.org/10.1182/blood-2015-11-679134

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.